FDA Approves Talzenna for Metastatic, Castration-Resistant Prostate Cancer

MONDAY, June 26, 2023 (HealthDay News) -- The U.S. Food and Drug Administration has approved Talzenna (talazoparib) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
The approval was based on a trial in which 399 patients with HRR gene-mutated mCRPC were randomly assigned (1:1) to receive enzalutamide 160 mg daily plus either talazoparib 0.5 mg or placebo daily.
The results of the trial showed statistically significant improvement in radiographic progression-free survival (rPFS) for Talzenna with enzalutamide versus placebo. Median rPFS was not reached in the Talzenna group versus 13.8 months with placebo (hazard ratio, 0.45; 95 percent confidence interval, 0.33 to 0.61; P < 0.0001). For 155 patients with BRCA-mutated mCRPC, the hazard ratio for rPFS was 0.20 (95 percent confidence interval, 0.11 to 0.36), but for HRR gene-mutated mCRPC without BRCA mutations, the hazard ratio was 0.72 (95 percent confidence interval, 0.49 to 1.07).
Recommended dosing is 0.5 mg orally once daily for Talzenna in combination with enzalutamide (160 mg orally daily) until disease progression or unacceptable toxicity. Patients receiving this combination should also receive a gonadotropin-releasing hormone analog concurrently or should have had bilateral orchiectomy.
The most common adverse reactions (≥10 percent) included decreased hemoglobin, neutrophils, lymphocytes, platelets, calcium, sodium, phosphate, magnesium, and potassium, as well as nausea, decreased appetite, fractures, dizziness, increased bilirubin, and dysgeusia. A blood transfusion was needed among 39 percent of patients treated with Talzenna with enzalutamide, including 22 percent who required multiple transfusions.
Approval of Talzenna was granted to Pfizer.
Related Posts
La cirugía de reemplazo de rodillas es menos riesgosa de lo que se piensa en los mayores de 80 años
MARTES, 22 de marzo de 2022 (HealthDay News) -- La cirugía de reemplazo de...
1.3 Million Older Women Still Receive Cervical Cancer Screening-Related Services
FRIDAY, Dec. 9, 2022 (HealthDay News) -- While annual use of cervical cancer...
Las diferencias conductuales condujeron a una alta tasa de mortalidad por COVID en el Sur de EE. UU.: estudio
VIERNES, 29 de abril de 2022 (HealthDay News) -- Se habrían podido evitar miles...
Un género podría sobresalir en la interpretación de los sentimientos de los demás
VIERNES, 30 de diciembre de 2022 (HealthDay News) -- Un nuevo estudio confirma...